159 results about "Anti fibrotic" patented technology

Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.

The present invention relates to improved methods of treating fibrotic or fibroproliferative disorders. Conjoint therapies are provided comprising the combination of one or more fibrocyte suppressors and one or more profibrotic factor antagonists or anti-fibrotic agents.

The present invention discloses 5-methyl-1-(substituted phenyl)-2(1H)-pyridones have enhanced anti-fibrotic activities than 5-methyl-1-(non-substituted phenyl)-2(1H)-pyridones. An representative example of 5-methyl-(1-substituted phenyl)-2(1H)-pyridones is 1-(3′-fluorophenyl)-5-methyl-2(1H)-pyridone. Accordingly, there are provided compositions comprising one or more compounds selected from the group consisting of 5-methyl-1-(substituted phenyl)-2(1H)-pyridones and methods of using the same to treat or prevent fibrosis diseases.

In this invention, we describe a group of flavonoids and flavonoid-containing extracts that have pharmaceutical properties which are useful in the medicinal therapy of fibrotic diseases for the treatment or reparation and prevention of fibrotic lesional tissues. Representative flavonoids and flavonoid-containing extracts have the active compositions of the below formula. Those compositions can be extracted and purified from the botanicals, including Scutellaria baicalensis Georgi, Scutellaria scordifolia Fisch,Oroxylum indicum(L.) Vent, Plantago major L. The compositions of the invention are novel as an anti-fibrotic drugs, as agents for treating fibrosis.

The present invention provides compounds having the general structural Formula (I):and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis or dysproliferation.

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

The present invention relates to improved methods of treating fibrotic or fibroproliferative disorders. Conjoint therapies are provided comprising the combination of one or more fibrocyte suppressors and one or more profibrotic factor antagonists or anti-fibrotic agents.

The present invention relates to compositions and methods for rendering medical devices less prone to fibrous encapsulation comprising the use of non-gaseous CO dissolved in a reservoir material. Upon exposure to a biological environment, non-gaseous CO is slowly desorbed and / or dissolved from the reservoir material which provides anti-fibrotic activity. These compositions and methods may be used directly on soft tissue implants and / or medical devices to treat and / or prevent conditions and disease states related to fibrosis. Furthermore, the compositions can be incorporated into materials that are used to create soft tissue implants and / or medical devices to imbue implants and devices with anti-fibrotic properties.

An anti-inflammatory and anti-fibrotic antioxidant formulation for treatment of hepatic oxidative stress and cirrhosis is disclosed. The antioxidant formulation can further include at least one of a hepatitis C virus-specific or a non-alcoholic steatohepatitis-specific formulation comprising one or more compounds to retard the progression of liver fibrosis and possibly reverse an established fibrosis. Methods of treatment or therapies for treating chronic liver disease and chronic hepatitis are also provided.

The invention discloses a traditional Chinese medicine composition for treating liver cirrhosis and fibrosis and a preparation method thereof. The traditional Chinese medicine composition is mainly prepared by the bulk drugs of radix salviae miltiorrhizae, black soya bean, red paeony root, ophiopogon root, astragalus root, radix codonopsis pilosulae, angelica, carapax amydae, rhizoma zedoariae, twotooth achyranthes root, Chinese yam, giant knotweed, hedyotis diffusa, fructus amomi and honey-fried licorice root. The prescription disclosed by the invention is complete in the matching of a monarch, a minister, an adjuvant and a conductant drug, is excellent in the efficacy of drugs, is flexible in application and has the comparatively obvious characteristic of traditional Chinese medicine. The traditional Chinese medicine composition disclosed by the invention has the actions of resisting the fibrosis, resisting hepatitis B virus (HBV) replication, improving the liver function, regulating the blood circulation of the liver, reinforcing the liver, softening hard masses, strengthening the spleen and the like; and the traditional Chinese medicine composition also has the actions of lowering the portal pressure, reducing the thickness of the spleen and improving the liver function. The traditional Chinese medicine composition disclosed by the invention has an obvious curative effect in the therapeutic action to the liver cirrhosis and fibrosis. In addition, the traditional Chinese medicine composition disclosed by the invention has an obvious action of resisting the liver cirrhosis and fibrosis of children.

The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and / or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-α and anti-TGF-β1 action for the treatment of hepatic fibrosis.

A medicament for treating or preventing fibrotic diseases contains an antifibrotic substance that is a (poly) peptide having antifibrotic activity and comprising at least one of an N-terminal procollagen (III) propeptide and a C-terminal procollagen (III) propeptide, or a fragment of the (poly) peptide defined having antifibrotic activity or a derivative of the (poly) peptide having antifibrotic activity. The antifibrotic substance is combined with a pharmaceutically tolerable carrier or dilutant.

A method for treating pulmonary hypertension and other diseases involving a defect in collagen metabolism, by administration of an effective amount of a liposome encapsulated copolymer conjugate antifibrotic composition, is disclosed. The antifibrotic agent is preferably proline analogs, such as cis-4-hydroxy-L-proline (CHOP), 3,4-dehydro-DL-proline (DHP), (R)-(-)-2-thiazolidine-4-carboxylic acid (THP), and (S)-(-)-2-azetidinecarboxylic acid (ACA). Consistent, high loadings (>90%) of the antifibrotic agent are achieved by first forming a dipeptide with L-lysine, after which the dipeptide is copolymerized with the polymer component to form the copolymer conjugate. The polymer is preferably poly(ethylene glycol) having a weight average molecular weight of from about 500 to about 15,000. Efficient delivery and consistent release of the antifibrotic agent inhibits collagen accumulation and treats the diseases involved. Accordingly, there is a substantial reduction in the quantity of antifibrotic agent necessary, and thus a corresponding reduction in the potential for toxicity that would otherwise result from its prolonged administration.

An anti-inflammatory and anti-fibrotic antioxidant formulation for treatment of hepatic oxidative stress and cirrhosis is disclosed. The antioxidant formulation can further include at least one of a hepatitis C virus-specific or a non-alcoholic steatohepatitis-specific formulation comprising one or more compounds to retard the progression of liver fibrosis and possibly reverse an established fibrosis. Methods of treatment or therapies for treating chronic liver disease and chronic hepatitis are also provided.

Methods and compositions for improving the delivery and / or efficacy of a therapy (e.g., an anti-cancer, anti-fibrotic or anti-inflammatory therapy) are disclosed. The invention is based, at least in part, on the discovery that metformin, a widely prescribed anti-diabetic drug, can affect the tumor microenvironment (e.g., directly, i.e., independent of its effects on cancer cells themselves or tumor metabolism). In embodiments described herein, metformin has been shown to reduce the amount of extracellular matrix, including collagen 1 and hyaluronan, in the fibro-inflammatory tumor microenvironment in a subject (e.g., a subject with a desmoplastic tumor).

The invention relates to methods of treating patients infected with human immunodeficiency virus (HIV) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs thereof.

The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and / or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-α and anti-TGF-β1 action for the treatment of hepatic fibrosis.

Provided are peptides that can inhibit collagen synthesis, processing and / or secretion from scar forming cells or fibroblasts. Also provided are methods for using the peptides to produce an anti-fibrotic, anti-scarring, anti-inflammatory, and / or pro-regenerative effect, e.g., on an injured or diseased tissue.

The invention relates to a new combination of an anti-MAdCAM antibody with an anti-fibrotic agent, such as a protease inhibitor, preferably a caspase inhibitor. The invention also relates to pharmaceutical compositions comprising the combination of the invention, and the use of the combination for the treatment of liver fibrosis.

Substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity; or derivatives thereof, analogues thereof, pharmaceutically acceptable salts thereof, and metabolites thereof; with the proviso that the compound is not Tranilast.

Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

The invention discloses a polydopamine-zwitterionic polymer anti-adhesion coating modification method. The method comprises the following steps: soaking a modified object in a mixed solution of trihydroxymethyl aminomethane, dopamine hydrochloride, a zwitterionic polymer and a strong electrolyte solution to form the anti-adhesion coating, and reducing foreign matter reaction in an anti-cell adhesion manner. Therefore, a long-term stable anti-fibrosis effect can be obtained without introducing drugs. According to the method, the polymer is firstly formed, and then the polymer is grafted to the surface of an electrode instead of directly initiating polymerization on the surface of the electrode, so that toxic small molecules are removed through sufficient dialysis before grafting, and good biocompatibility is ensured. By utilizing the anti-polyelectrolyte effect of zwitterions, the electrolyte is added into the coating solution, so that the solubility of the zwitterionic polymer can be increased, and the high grafting density is ensured.

The present invention relates to a composition for inhibiting fibrosis and more specifically, to a composition for inhibiting fibrosis, wherein the composition is effective in inhibiting fibrosis of tissue cells by containing a peptide derived from telomerase. The peptide according to the present invention exhibits an effect of inhibiting the progression of various kinds of fibrosis, including fibrosis due to occurrence of cancer, fibrosis due to the administration of chemotherapy anticancer drugs, fibrosis due to the exposure to radiation, or progressive fibrosis of tissues, including a TGF-β signaling procedure, and thus can provide a composition for anti-fibrosis or inhibiting fibrosis and a method for treating diseases due to fibrosis.

The invention provides a preparation method and applications of a lamivudine twin drug. Lamivudine, and ursolic acid or oleanolic acid are condensed into the lamivudine-ursolic acid or lamivudine-oleanolic acid twin drug at a low temperature by using ethyl chloroacetate (ethyl bromoacetate) or ethyl chloropropionate (ethyl bromopropionate) as the linking group. The twin drug possibly has a dual-action mechanism; and the twin drug has the action of antivirus, and also has the actions of resisting inflammations, protecting the liver cell membranes, improving the liver function and resisting fibrosis. Thus, the invention organically combines the antivirus therapy and the liver protection treatment and provides a new concept for the research and development of drugs for treating hepatitis.

The invention provides a traditional Chinese medicine composition for treating chronic kidney diseases and chronic renal failure. The traditional Chinese medicine composition is prepared from radix et rhizoma rhei preparata, Chinese peashrub roots, herba centellae, rhizoma curcumae, radix salviae miltiorrhizae, rhizoma smilacis glabrae, flos carthami, rhizoma polygoni cuspidati, herba pyrolae, lucid ganoderma, radix astragali and fructus aurantii. The radix et rhizoma rhei preparata has the effects of promoting blood circulation, detoxifying and eliminating turbidity, the Chinese peashrub roots has the effects of dispelling wind, detoxifying and reducring urinary protein, the herba centellae has the effects of dispelling wind, detoxifying and reducing creatinine, the rhizoma curcumae has the effects of breaking blood, promoting qi and resisting fibrosis, the radix salviae miltiorrhizae and the flos carthami have the effects of promoting blood circulation and removing blood stasis, the rhizoma smilacis glabrae has the effects of clearing heat, detoxifying and drying dampness, the rhizoma polygoni cuspidati has the effects of dispelling wind, detoxifying and reducing uric acid, the herba pyrolae has the effects of tonifying kidney and clearing away dieresis, the lucid ganoderma and the radix astragali have the effects of invigorating qi and strengthening health, and the fructus aurantii has the effects of soothing liver and regulating qi. The traditional Chinese medicine composition can effectively reduce proteinuria and hematuria of patients with chronic kidney diseases, relieve renal function progression of chronic renal failure, reduce serum creatinine, improve clinical symptoms of patients with chronic kidney diseases, especially chronic renal failure, and protect renal functions.